Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$21.90 +1.3%	$21.81	$15.47 ▼ $36.37	$739.68M	1.2	232,703 shs	206,226 shs
IMNM Immunome	$9.67 +15.1%	$8.72	$5.15 ▼ $16.81	$730.90M	1.92	903,876 shs	1.78 million shs
MNPR Monopar Therapeutics	$41.07 +3.3%	$35.63	$1.72 ▼ $54.30	$243.14M	1.01	362,258 shs	26,967 shs
PHAR Pharming Group	$9.95 -1.5%	$10.61	$6.65 ▼ $12.61	$692.34M	0.02	6,077 shs	735 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	+1.30%	+2.62%	-13.85%	+20.73%	+10.49%
IMNM Immunome	+15.12%	+8.77%	+1.36%	+22.25%	-34.04%
MNPR Monopar Therapeutics	+3.29%	+1.56%	+20.02%	+3.74%	+1,011.50%
PHAR Pharming Group	-1.49%	-0.60%	-11.92%	+24.06%	+16.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	2.2839 of 5 stars	4.6	0.0	2.9	0.8	0.0
IMNM Immunome	2.1418 of 5 stars	3.5	0.0	4.0	2.5	0.0
MNPR Monopar Therapeutics	2.3942 of 5 stars	3.4	2.0	3.1	2.5	0.0
PHAR Pharming Group	2.063 of 5 stars	3.5	3.0	2.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	79.39% Upside
IMNM Immunome	3.00	Buy	$23.33	141.30% Upside
MNPR Monopar Therapeutics	2.83	Moderate Buy	$60.00	46.09% Upside
PHAR Pharming Group	3.00	Buy	$30.00	201.51% Upside

Current Analyst Ratings Breakdown

Latest MNPR, AVBP, PHAR, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	AVBP ArriVent BioPharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy	$33.00
7/7/2025	MNPR Monopar Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/23/2025	MNPR Monopar Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	IMNM Immunome	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00 ➝ $21.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
IMNM Immunome	$9.04M	93.07	N/A	N/A	$2.27 per share	4.26
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$9.02 per share	N/A
PHAR Pharming Group	$297.20M	2.29	$0.07 per share	136.32	$3.25 per share	3.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
MNPR Monopar Therapeutics	-$15.59M	-$3.48	N/A	N/A	N/A	N/A	-55.39%	-51.53%	8/8/2025 (Estimated)
PHAR Pharming Group	-$11.84M	-$0.20	N/A	331.67	N/A	-4.14%	-6.01%	-3.23%	7/30/2025 (Estimated)

Latest MNPR, AVBP, PHAR, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AVBP ArriVent BioPharma	-$0.70	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	IMNM Immunome	-$0.52	N/A	N/A	N/A	$1.03 million	N/A
8/8/2025	N/A	MNPR Monopar Therapeutics	-$0.47	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	PHAR Pharming Group	-$0.15	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	MNPR Monopar Therapeutics	-$0.65	-$0.38	+$0.27	-$0.38	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
IMNM Immunome	N/A	10.49	10.49
MNPR Monopar Therapeutics	N/A	36.91	36.91
PHAR Pharming Group	0.39	2.76	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
IMNM Immunome	44.58%
MNPR Monopar Therapeutics	1.83%
PHAR Pharming Group	0.03%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
IMNM Immunome	8.60%
MNPR Monopar Therapeutics	20.50%
PHAR Pharming Group	2.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
IMNM Immunome	40	87.01 million	79.53 million	Optionable
MNPR Monopar Therapeutics	10	6.12 million	4.86 million	Not Optionable
PHAR Pharming Group	280	68.51 million	67.10 million	Not Optionable

MNPR, AVBP, PHAR, and IMNM Headlines

Recent News About These Companies

Pharming Group N.V. (PHGUF) stock price, news, quote & history ...

July 11, 2025 | sg.finance.yahoo.com

Pharming Group (NASDAQ:PHAR) Trading Down 3.5% - Should You Sell?

July 9, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Up - What's Next?

July 8, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Shares Gap Down - What's Next?

July 3, 2025 | marketbeat.com

AS:PHAR Financials | Pharming Group NV - Investing.com

July 2, 2025 | investing.com

Pharming Group (NASDAQ:PHAR) Stock Price Down 4.9% - Here's What Happened

July 1, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume - Here's Why

June 30, 2025 | marketbeat.com

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS ...

June 25, 2025 | morningstar.comM

Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve ... - Nasdaq

June 25, 2025 | nasdaq.com

Pharming Group (NASDAQ:PHAR) Shares Down 3.2% - Here's Why

June 18, 2025 | marketbeat.com

Pharming Group (NASDAQ:PHAR) Sees Strong Trading Volume - Here's What Happened

June 17, 2025 | marketbeat.com

European Penny Stocks Under €200M Market Cap To Watch

June 13, 2025 | uk.finance.yahoo.com

Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

June 11, 2025 | finance.yahoo.com

Pharming Group Announces Key Board Appointments and Approvals at 2025 AGM

June 11, 2025 | tipranks.com

Pharming Group to participate in June investor conferences

May 28, 2025 | finance.yahoo.com

Pharming Group to participate in June investor conferences | PHARM Stock News

May 28, 2025 | gurufocus.com

Pharming Group First Quarter 2025 Earnings: US$0.022 loss per share (vs US$0.019 loss in 1Q 2024)

May 10, 2025 | finance.yahoo.com

Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Pharming Group N.V. 2025 Q1 - Results - Earnings Call Presentation

May 9, 2025 | seekingalpha.com

Pharming Group’s Strong Financial Performance and Strategic Growth Drive Buy Rating

May 8, 2025 | tipranks.com

Pharming Group N.V.: Pharming Group reports first quarter 2025 financial results and provides business update

May 8, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
3 High-Risk, High-Reward Stocks With Explosive Upside
By Nathan Reiff | July 16, 2025
View 3 High-Risk, High-Reward Stocks With Explosive Upside
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains

MNPR, AVBP, PHAR, and IMNM Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$21.90 +0.28 (+1.30%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$21.90 0.00 (0.00%)

As of 07/16/2025 04:02 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Immunome NASDAQ:IMNM

$9.67 +1.27 (+15.12%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$9.60 -0.07 (-0.78%)

As of 04:14 AM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Monopar Therapeutics NASDAQ:MNPR

$41.07 +1.31 (+3.29%)

Closing price 07/16/2025 04:00 PM Eastern

Extended Trading

$41.61 +0.54 (+1.31%)

As of 07/16/2025 07:18 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Pharming Group NASDAQ:PHAR

$9.95 -0.15 (-1.49%)

Closing price 07/16/2025 03:58 PM Eastern

Extended Trading

$10.20 +0.25 (+2.55%)

As of 05:30 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time